Agios Pharmaceuticals’ (AGIO) “Outperform” Rating Reaffirmed at Royal Bank of Canada

Royal Bank of Canada reissued their outperform rating on shares of Agios Pharmaceuticals (NASDAQ:AGIO) in a research note released on Friday morning, Benzinga reports. They currently have a $55.00 target price on the biopharmaceutical company’s stock.

A number of other equities analysts have also recently weighed in on AGIO. Raymond James reiterated an “outperform” rating and set a $51.00 price target on shares of Agios Pharmaceuticals in a report on Thursday, October 10th. StockNews.com raised shares of Agios Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Wednesday, October 16th. Cantor Fitzgerald reissued an “overweight” rating on shares of Agios Pharmaceuticals in a research note on Friday, September 20th. Leerink Partnrs cut shares of Agios Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Friday, September 27th. Finally, Leerink Partners lowered Agios Pharmaceuticals from an “outperform” rating to a “market perform” rating and cut their target price for the company from $60.00 to $56.00 in a research report on Friday, September 27th. One investment analyst has rated the stock with a sell rating, four have given a hold rating and four have assigned a buy rating to the stock. According to data from MarketBeat, Agios Pharmaceuticals has an average rating of “Hold” and an average price target of $52.33.

Agios Pharmaceuticals Trading Up 1.0 %

AGIO stock traded up $0.44 during trading on Friday, reaching $44.87. 672,853 shares of the stock were exchanged, compared to its average volume of 689,661. The business has a 50 day moving average price of $44.62 and a 200-day moving average price of $42.13. Agios Pharmaceuticals has a 1 year low of $20.40 and a 1 year high of $53.28. The firm has a market capitalization of $2.55 billion, a price-to-earnings ratio of -6.90, a P/E/G ratio of 0.47 and a beta of 0.75.

Agios Pharmaceuticals (NASDAQ:AGIO) last released its quarterly earnings data on Thursday, August 1st. The biopharmaceutical company reported ($1.69) EPS for the quarter, missing analysts’ consensus estimates of ($1.60) by ($0.09). The business had revenue of $8.60 million during the quarter, compared to analyst estimates of $9.34 million. Agios Pharmaceuticals had a negative net margin of 1,165.69% and a negative return on equity of 47.05%. The company’s revenue was up 28.4% on a year-over-year basis. During the same quarter in the prior year, the company posted ($1.51) earnings per share. On average, research analysts anticipate that Agios Pharmaceuticals will post 7.54 EPS for the current year.

Insider Transactions at Agios Pharmaceuticals

In other Agios Pharmaceuticals news, CEO Brian Goff sold 11,091 shares of the stock in a transaction dated Thursday, August 8th. The stock was sold at an average price of $42.75, for a total value of $474,140.25. Following the sale, the chief executive officer now owns 78,792 shares of the company’s stock, valued at $3,368,358. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. In other news, CEO Brian Goff sold 11,091 shares of Agios Pharmaceuticals stock in a transaction on Thursday, August 8th. The shares were sold at an average price of $42.75, for a total transaction of $474,140.25. Following the completion of the sale, the chief executive officer now directly owns 78,792 shares of the company’s stock, valued at approximately $3,368,358. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO Cecilia Jones sold 2,542 shares of the firm’s stock in a transaction on Thursday, September 26th. The shares were sold at an average price of $49.03, for a total value of $124,634.26. Following the completion of the sale, the chief financial officer now owns 20,158 shares in the company, valued at approximately $988,346.74. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 4.93% of the company’s stock.

Hedge Funds Weigh In On Agios Pharmaceuticals

A number of institutional investors and hedge funds have recently added to or reduced their stakes in AGIO. Farallon Capital Management LLC boosted its holdings in shares of Agios Pharmaceuticals by 1.1% in the 2nd quarter. Farallon Capital Management LLC now owns 5,654,502 shares of the biopharmaceutical company’s stock valued at $243,822,000 after buying an additional 63,900 shares in the last quarter. Vanguard Group Inc. boosted its stake in Agios Pharmaceuticals by 0.8% in the first quarter. Vanguard Group Inc. now owns 5,572,021 shares of the biopharmaceutical company’s stock valued at $162,926,000 after acquiring an additional 44,583 shares in the last quarter. Price T Rowe Associates Inc. MD boosted its stake in Agios Pharmaceuticals by 23.9% in the first quarter. Price T Rowe Associates Inc. MD now owns 2,012,993 shares of the biopharmaceutical company’s stock valued at $58,861,000 after acquiring an additional 388,381 shares in the last quarter. Marshall Wace LLP grew its holdings in shares of Agios Pharmaceuticals by 307.8% during the second quarter. Marshall Wace LLP now owns 1,133,735 shares of the biopharmaceutical company’s stock worth $48,887,000 after purchasing an additional 855,739 shares during the last quarter. Finally, BNP PARIBAS ASSET MANAGEMENT Holding S.A. increased its position in shares of Agios Pharmaceuticals by 5.9% during the first quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 1,108,613 shares of the biopharmaceutical company’s stock worth $32,416,000 after purchasing an additional 62,153 shares in the last quarter.

Agios Pharmaceuticals Company Profile

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.